SIMPONI 50 MG/0.5 ML SYRINGE

What it is

SIMPONI 50 MG/0.5 ML SYRINGE is how the CMS NADAC file names this product. The FDA NDC Directory lists it as golimumab, under the trade name “Simponi”.

FDA gives its dosage form as injection, solution and its route as subcutaneous.

The labeler, the company named on the label, is Janssen Biotech, Inc.

FDA’s Established Pharmacologic Class for it is Tumor Necrosis Factor Blocker.

The NADAC file of 2026-10-14 prices it under one NDC (National Drug Code), 57894-0070-01.

NADAC classes it as a brand-name drug (rate-setting class B), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $6,488.62 for 0.5 mL (0.5 × $12,977.244 per ML, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-01-02. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation codes for it: 4, carried forward from the previous file; 5, calculated based on package size.

This NDC’s NADAC was carried forward from an earlier file (NADAC explanation code 2 or 4), not newly surveyed: it took effect on 2026-01-02. The file is new; the price is not.

What NADAC measures · NADAC explanation codes · Carried-forward prices

The NDC

• 57894-0070-01 · Janssen Biotech, Inc. · $12,977.244 per ML · eff. 2026-01-02 filed carried forward

Other strengths, forms and brands

1 other product in the NADAC file shares the FDA nonproprietary name golimumab with SIMPONI 50 MG/0.5 ML SYRINGE.

Part D is one average per brand and generic name, over every strength and form.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-01-02, 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18

Compared with its class

Its NADAC price is $12,977.244 per ML filed.

Of the 10 other products in FDA’s Tumor Necrosis Factor Blocker class priced per ML, 0 have a higher middle NADAC price and 10 a lower one. The one in the middle is ADALIMUMAB-ADAZ(CF) PEN 40 MG/0.4 ML, at $1,587.81765 per ML filed (eff. 2026-09-23).

Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-01-02, 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

How the class comparison works

What Medicare paid

Medicare Part D paid $5,665.00 for 0.5 mL, at an average of $11,330.00127 per ML in 2024 (2024-01-01 to 2024-12-31) for “Simponi” and “Golimumab”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).

That average covers 25,616 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.

Medicare's price is not your price.

What Part D spending measures · Which Medicare figure OpenBill compares · How the spread is worked out

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

• What is your cash price for 0.5 mL? Is it lower than what I would pay through my insurance?
• How much is in the package I am getting? This page uses 0.5 mL; your package may hold a different amount.
• If you have Medicare Part D: what is my plan’s copay or coinsurance for it? The Part D average on this page is not what you pay.
• These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.